Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (1091-1100 of 1,482) with videos related to

Pageof 149
Sort By:
Pathogens & Immunity|February 6, 2025
The TB27 Transcriptomic Model for Predicting <i>Mycobacterium tuberculosis</i> Culture ConversionMaja Reimann, Korkut Avsar, Andrew R DiNardo, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer Immunology Research|June 7, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal HyperexpansionPoonam N Desai, Bofei Wang, Andre Fonseca, et al.
Cancer Immunology Research|May 10, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal HyperexpansionPoonam N Desai, Bofei Wang, Andre Fonseca, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Nature Communications|July 12, 2018
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypesKoichi Takahashi, Feng Wang, Kiyomi Morita, et al.
Trials|October 4, 2023
Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responsesAndrew R DiNardo, Moshe Arditi, Ashish M Kamat, et al.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
Pageof 149

Showing results (1091-1100 of 1,482) with videos related to

Sort By:
Pageof 149
Pathogens & Immunity|February 6, 2025
The TB27 Transcriptomic Model for Predicting <i>Mycobacterium tuberculosis</i> Culture ConversionMaja Reimann, Korkut Avsar, Andrew R DiNardo, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer Immunology Research|June 7, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal HyperexpansionPoonam N Desai, Bofei Wang, Andre Fonseca, et al.
Cancer Immunology Research|May 10, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal HyperexpansionPoonam N Desai, Bofei Wang, Andre Fonseca, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Nature Communications|July 12, 2018
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypesKoichi Takahashi, Feng Wang, Kiyomi Morita, et al.
Trials|October 4, 2023
Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responsesAndrew R DiNardo, Moshe Arditi, Ashish M Kamat, et al.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
Pageof 149